USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
COLLAGEN MEDICAL, LLC
Address:
COLLAGEN MEDICAL, LLC
23 OAK ST
BELMONT, MA 02478-3006
Phone:
N/A
URL:
EIN:
127482262
DUNS:
967097218
Number of Employees:
3
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $604,656.00 3
SBIR Phase II $1,220,519.00 1

Award List:

Optimization of Efficacy and Safety Pharamacology of Fibrosis Imaging Agent CM-65

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$189,822.00
Agency:
HHS
Principal Investigator:
Andrew F. Kolodziej – 617-643-0193
Abstract:
DESCRIPTION (provided by applicant): Dramatic increases in the incidence of obesity, diabetes, and the metabolic syndrome are increasing the prevalence of chronic liver diseases. Liver fibrosis arising from an excessive deposition of type I collagen in theparenchyma, occurs in advanced stages of… More

CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$207,280.00
Agency:
HHS
Principal Investigator:
Valerie Humblet – 617-642-0585
Abstract:
DESCRIPTION (provided by applicant): Assessment of myocardial perfusion is a gatekeeper diagnostic exam that has high sensitivity for identifying individuals with ischemic heart disease. Millions of perfusion studies are performed annually in the US usinga stress/rest paradigm with a radioactive… More

Optimization of Efficacy and Safety Pharamacology of Fibrosis Imaging Agent CM-65

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,220,519.00
Agency:
HHS
Principal Investigator:
Andrew F. Kolodziej – 617-643-0193
Abstract:
DESCRIPTION (provided by applicant): Dramatic increases in the incidence of obesity, diabetes, and the metabolic syndrome are increasing the prevalence of chronic liver diseases. Liver fibrosis arising from an excessive deposition of type I collagen in theparenchyma, occurs in advanced stages of… More

IGF::OT::IGF MR Contrast Agent to Quantify Myocardial Fibrosis - SBIR Topic 072 -

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$207,554.00
Agency:
HHS
Principal Investigator:
Scott Turner – 617-970-3817
Abstract:
Myocardial fibrosis is a crucial marker of adverse cardiac remodeling. Research suggests a strong correlationbetween the extent of myocardial fibrosis and adverse myocardial remodeling that occurs after ischemic injury orduring the progression of cardiomyopathies and heart failure. Diffuse… More